30 results
8-K
EX-99.1
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
: topline data expected in Q2 2024
Presented positive data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients at American Society
8-K
EX-99.2
s3ia6xbxmwwr5 al
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
EX-99.1
frb9ubuvj1an8cn1m
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
424B5
7rqvk6a
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
h0oub5tz5m3cp10 76v
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
gh2iuvfrhiw
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
425
xkbata5js
27 Sep 22
Business combination disclosure
9:30am
8-K
EX-99.1
vd57e2l mff0h2m
27 Sep 22
Other Events
9:28am
8-K
EX-99.1
83chk
15 Aug 22
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
4:22pm
8-K
7rkh2vb5
25 Apr 22
Other Events
8:05am
8-K
EX-99.1
um09jatux
23 Mar 22
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
4:05pm